Akero Sees Across-The-Board NASH Benefit With Efruxifermin, But Faces Competition

 
• By Joseph Haas
Competitive edge and business advantage concept as a group of hot air balloons racing to the top but an individualleader with a small balloon attached giving the winning competitor an extra boost.
Akero hopes to stay ahead of other FGF21 analogs in NASH

More from Strategy

More from Business